These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21748824)

  • 21. Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen.
    Becker S; Ardisson V; Lepareur N; Sergent O; Bayat S; Noiret N; Gaboriau F; Clément B; Boucher E; Raoul JL; Garin E
    Nucl Med Biol; 2010 Oct; 37(7):777-84. PubMed ID: 20870152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
    World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma.
    Brans B; Van Laere K; Gemmel F; Defreyne L; Vanlangenhove P; Troisi R; Van Vlierberghe H; Colle I; De Hemptinne B; Dierckx RA
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):928-32. PubMed ID: 12111134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up.
    Ahmadzadehfar H; Habibi E; Ezziddin S; Wilhelm K; Fimmers R; Spengler U; Palmedo H; Strunk H; Schild HH; Biersack HJ; Risse J
    Nuklearmedizin; 2014; 53(2):46-53. PubMed ID: 24468919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient dosimetry for 131I-lipiodol therapy.
    Monsieurs MA; Bacher K; Brans B; Vral A; De Ridder L; Dierckx RA; Thierens HM
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):554-61. PubMed ID: 12690415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary lipiodol embolism after transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report and literature review.
    Naorungroj T; Naksanguan T; Chinthammitr Y
    J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S270-5. PubMed ID: 23590054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
    Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call(®)) in patients with unresectable hepatocellular carcinoma.
    Yamashita Y; Taketomi A; Itoh S; Harimoto N; Morita K; Fukuhara T; Ueda S; Sanefuji K; Sugimachi K; Tajima T; Maehara Y
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):301-7. PubMed ID: 19495755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of iodized oil within the liver after hepatic arterial injection.
    Park CH; Thakur ML; Madsen MT
    Radiology; 1987 Aug; 164(2):585-6. PubMed ID: 3037593
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems.
    Dubbelboer IR; Lilienberg E; Ahnfelt E; Sjögren E; Axén N; Lennernäs H
    Ther Deliv; 2014 Apr; 5(4):447-66. PubMed ID: 24856170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
    Idée JM; Guiu B
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebral Lipiodol Embolism in Hepatocellular Carcinoma Patients Treated with Transarterial Embolization/Chemoembolization.
    Chu HJ; Lee CW; Yeh SJ; Tsai LK; Tang SC; Jeng JS
    PLoS One; 2015; 10(6):e0129367. PubMed ID: 26107693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study.
    Subramanian S; Das T; Chakraborty S; Sarma HD; Banerjee S; Samuel G; Venkatesh M
    Cancer Biother Radiopharm; 2010 Oct; 25(5):539-43. PubMed ID: 20849309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma.
    Beppu T; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Ogura S; Kasai C; Kusagawa S; Nojiri K; Yoneda M; Fuke H; Yamamoto N; Takei Y; Fujimori M; Hasegawa T; Yamanaka T; Uraki J; Kashima M; Takaki H; Nakatsuka A; Yamakado K; Takeda K
    Anticancer Res; 2012 Nov; 32(11):4923-30. PubMed ID: 23155261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma.
    Chua TC; Chu F; Butler SP; Quinn RJ; Glenn D; Liauw W; Morris DL
    Cancer; 2010 Sep; 116(17):4069-77. PubMed ID: 20564150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.
    Boucher E; Corbinais S; Rolland Y; Bourguet P; Guyader D; Boudjema K; Meunier B; Raoul JL
    Hepatology; 2003 Nov; 38(5):1237-41. PubMed ID: 14578862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipiodol embolism following transarterial chemoembolization: an atypical case.
    Taupin D; Mukherjee V; Nathavitharana R; Green DA; Fridman D
    Crit Care Med; 2014 Jun; 42(6):e481-4. PubMed ID: 24607940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
    Lau WY; Lai EC; Leung TW; Yu SC
    Ann Surg; 2008 Jan; 247(1):43-8. PubMed ID: 18156922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.